161 related articles for article (PubMed ID: 26851018)
21. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
22. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
[TBL] [Abstract][Full Text] [Related]
23. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells.
Ye D; Mendelsohn J; Fan Z
Clin Cancer Res; 1999 Aug; 5(8):2171-7. PubMed ID: 10473102
[TBL] [Abstract][Full Text] [Related]
24. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
[TBL] [Abstract][Full Text] [Related]
25. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells.
Kai L; Levenson AS
Anticancer Res; 2011 Oct; 31(10):3323-30. PubMed ID: 21965742
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate.
Kim W; Jones JO; Diamond M; Haqq C; Molina A; Small EJ; Ryan CJ
Prostate Cancer Prostatic Dis; 2014 Sep; 17(3):292-9. PubMed ID: 25047002
[TBL] [Abstract][Full Text] [Related]
27. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C
Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
[TBL] [Abstract][Full Text] [Related]
28. Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft.
Gregory CW; Johnson RT; Presnell SC; Mohler JL; French FS
J Androl; 2001; 22(4):537-48. PubMed ID: 11451350
[TBL] [Abstract][Full Text] [Related]
29. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
Björkman M; Iljin K; Halonen P; Sara H; Kaivanto E; Nees M; Kallioniemi OP
Int J Cancer; 2008 Dec; 123(12):2774-81. PubMed ID: 18798265
[TBL] [Abstract][Full Text] [Related]
30. Ribozyme-mediated inhibition of PKCalpha sensitizes androgen-independent human prostate cancer cells to cisplatin-induced apoptosis.
Orlandi L; Binda M; Folini M; Bearzatto A; Villa R; Daidone MG; Zaffaroni N
Prostate; 2003 Feb; 54(2):133-43. PubMed ID: 12497586
[TBL] [Abstract][Full Text] [Related]
31. Expression profiles and functional associations of endogenous androgen receptor and caveolin-1 in prostate cancer cell lines.
Bennett NC; Hooper JD; Johnson DW; Gobe GC
Prostate; 2014 May; 74(5):478-87. PubMed ID: 24375805
[TBL] [Abstract][Full Text] [Related]
32. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.
Mashima T; Okabe S; Seimiya H
Mol Pharmacol; 2010 Nov; 78(5):846-54. PubMed ID: 20709811
[TBL] [Abstract][Full Text] [Related]
34. Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence.
D'Antonio JM; Ma C; Monzon FA; Pflug BR
Prostate; 2008 May; 68(7):698-714. PubMed ID: 18302219
[TBL] [Abstract][Full Text] [Related]
35. Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation.
Yin Y; Li R; Xu K; Ding S; Li J; Baek G; Ramanand SG; Ding S; Liu Z; Gao Y; Kanchwala MS; Li X; Hutchinson R; Liu X; Woldu SL; Xing C; Desai NB; Feng FY; Burma S; de Bono JS; Dehm SM; Mani RS; Chen BPC; Raj GV
Cancer Res; 2017 Sep; 77(18):4745-4754. PubMed ID: 28754673
[TBL] [Abstract][Full Text] [Related]
36. A novel GPCR target in correlation with androgen deprivation therapy for prostate cancer drug discovery.
Tian JY; Chi CL; Bian G; Guo FJ; Wang XQ; Yu B
Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):195-203. PubMed ID: 32991779
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survival.
Gestaut MM; Antoon JW; Burow ME; Beckman BS
Pharmacol Rep; 2014 Feb; 66(1):174-8. PubMed ID: 24905325
[TBL] [Abstract][Full Text] [Related]
38. SEMA3A-mediated crosstalk between prostate cancer cells and tumor-associated macrophages promotes androgen deprivation therapy resistance.
Liu F; Wang C; Huang H; Yang Y; Dai L; Han S; Xing N; Ren S
Cell Mol Immunol; 2021 Mar; 18(3):752-754. PubMed ID: 33558684
[No Abstract] [Full Text] [Related]
39. Novel steroidal 1,3,4-thiadiazines: Synthesis and biological evaluation in androgen receptor-positive prostate cancer 22Rv1 cells.
Komendantova AS; Scherbakov AM; Komkov AV; Chertkova VV; Gudovanniy AO; Chernoburova EI; Sorokin DV; Dzichenka YU; Shirinian VZ; Volkova YA; Zavarzin IV
Bioorg Chem; 2019 Oct; 91():103142. PubMed ID: 31400555
[TBL] [Abstract][Full Text] [Related]
40. Rezvilutamide: yet another androgen receptor pathway inhibitor for metastatic hormone-sensitive prostate cancer?
Aragon-Ching JB
Chin Clin Oncol; 2023 Apr; 12(2):12. PubMed ID: 37038056
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
